Written and maintained by CASRAI Editorial Board
Published
On this page
Drug formulation is the composition of a medicine: its active ingredient and other ingredients, selected to produce a suitable drug product. Formulation development establishes how those components work together, how the product can be manufactured consistently, and whether its intended quality and performance are maintained.
Short answer
A useful way to understand drug formulation is to separate three questions: what is in the product, what each component does, and what evidence supports the combination. An ingredient list answers the first question. Compatibility studies, performance tests and stability evidence address the others. This distinction connects the NIH definition of formulation with the product-development expectations in FDA’s Q8(R2) guidance and EMA’s excipient guideline.
The evidence comparison in the data table below brings those documents together. It maps formulation features to the technical records that explain them, including excipient grade, component compatibility, function-related controls and antimicrobial preservation. It is a reading aid for laboratory and pharmaceutical staff, rather than a formula for preparing a medicine or a universal testing specification.
Definition and scope
The NIH Clinicalinfo glossary defines formulation in terms of the composition of a drug product containing active and inactive ingredients. FDA distinguishes an active ingredient by its intended pharmacological activity or other direct effect. An inactive ingredient is another component of the product. The distinction describes a component’s role in that particular product; FDA notes that a substance can have an active role in one formulation and an inactive role in another.
Excipients are the constituents apart from the active substance. EMA lists functions including filling, disintegration, lubrication, stabilisation, thickening, emulsification and solubilisation. These functions explain why a medicine’s composition cannot be understood from the active ingredient alone. The relevant question is how the components support the intended product, including its stability and manufacturability.
Formulation development is part of the broader pharmaceutical-development work described in ICH Q8 pharmaceutical development. That work considers the drug substance, excipients, manufacturing process, container and closure, and relevant delivery device. The formula describes composition; the development record explains the scientific basis for selecting it.
Q8(R2) addresses the pharmaceutical-development section of a marketing submission. Its stated submission scope excludes the clinical-research stages, although its principles are relevant during those stages. FDA also identifies the guidance as nonbinding recommendations. Describing this framework as a universal legal requirement for every laboratory formulation would overstate its scope.
How drug formulation is used in practice
The intended product defines the development questions
In Q8(R2), the quality target product profile describes the intended quality characteristics that guide development. Relevant considerations include the route of administration, dosage form, release or delivery characteristics, stability and container system. The aim is a product and manufacturing process that consistently deliver the intended performance.
That starting point determines which material properties warrant study. FDA identifies solubility, water content, particle size, crystal properties, biological activity and permeability as possible drug-substance considerations. They can interact, so their importance depends on the actual product. The guidance does not assign every formulation the same particle-size limit or require the same tests regardless of dosage form.
Pharmaceutical formulation and excipient function
FDA asks for discussion of the chosen excipients, their concentration and the characteristics that influence product performance or manufacture. This includes compatibility with the active substance and, where relevant, compatibility among excipients. It also includes demonstrating that an excipient can fulfil its intended function throughout the product’s shelf life.
EMA adds a useful documentation distinction. The composition section identifies an excipient and its function; the development section explains the choice and compatibility; the specification section sets out its controls. A familiar material name may not sufficiently identify functional properties, in which case EMA calls for the commercial grade to be specified. A pharmacopoeial specification can also need additional tests related to the material’s intended function.
The final composition has a development history
Q8(R2) calls for a summary of the formulation’s evolution from the initial concept to the final design. Relevant changes between clinical, stability and proposed commercial formulations should be described and justified. Comparative evidence, such as dissolution or bioequivalence studies where appropriate, links the formulations used in development with the proposed commercial product.
Manufacturing knowledge is part of this explanation. FDA asks sponsors to discuss significant differences in the processes and equipment used for relevant batches and their effect on product quality and performance. The fact that two batches share an ingredient list does not, by itself, answer how their manufacturing differences were evaluated.
Packaging and performance are evaluated together
The container is another part of the development assessment. Q8(R2) addresses protection from moisture and light, container integrity, compatibility with the formulation, sorption and leaching. Where a delivery device is used, the guidance also calls for demonstrating accurate and reproducible delivery under conditions that simulate use as far as possible.
These issues connect formulation with pharmaceutical stability testing. A product’s stability evidence supports the proposed product and packaging arrangement. A composition record without its associated container, storage and performance evidence gives an incomplete account of development.
For products intended for reconstitution or dilution, Q8(R2) also addresses compatibility with the relevant diluents and admixtures. Its examples include precipitation and stability, with evidence supporting the labelled conditions of use. This is a distinct question from whether the unopened product remains within specification. In a technical record, the formulation before preparation and the product under its intended conditions of use therefore need to be connected by the appropriate compatibility evidence. That distinction explains why a storage study alone cannot answer every question about subsequent product performance.
Types and related concepts
Drug formulation can be discussed by dosage form, by the function of its components, or by the evidence needed to characterise the product. These are complementary descriptions. Calling something a tablet identifies a presentation; calling an ingredient a disintegrant identifies a function. Neither description supplies the full formulation or its quality justification.
Dosage forms have different relevant quality attributes
The Q8(R2) annex describes critical quality attributes as physical, chemical, biological or microbiological characteristics that need appropriate limits, ranges or distributions to ensure desired quality. For solid oral forms, typical concerns include purity, strength, drug release and stability. Other delivery systems can introduce additional concerns: aerodynamic properties for inhaled products, sterility for parenterals and adhesion for transdermal patches.
This provides a more useful comparison than treating every formulation as a variation on a tablet recipe. The attributes follow the intended product. A characteristic relevant to one delivery system does not automatically become a release criterion for every other formulation, and the guidance’s examples do not supply universal acceptance limits.
Functional properties and novelty are separate questions
EMA distinguishes established excipient specifications from characteristics relevant to performance in a particular product. Its examples include the capacity to emulsify or disperse and to provide appropriate viscosity. Such properties can matter even when the material already has a pharmacopoeial monograph.
Novelty is a different issue. EMA’s definition includes first use in a drug product or use by a new route of administration. For novel excipients, its guideline describes additional manufacturing, characterisation, control and supporting safety information. Familiarity with a substance’s name therefore does not establish that every proposed pharmaceutical use has the same evidence base.
Where formulation matters for labs and supply records
For laboratory staff, the practical connection is between a development question, the tested material and the resulting evidence. For staff reviewing technical supply records, it is the connection between the named ingredient, the specified grade and the function documented for the product. EMA’s composition and specification sections, together with FDA’s development guidance, provide a basis for asking precise questions about those records.
The following checklist is an editorial synthesis of those sources. It helps interpret a technical file; it does not prescribe a manufacturing procedure or add regulatory obligations.
- Identity and function: distinguish the active substance from each excipient and identify the documented role of each component. EMA’s composition section calls for the excipient’s name, quantity, function and reference standard.
- Material definition: establish whether the name identifies the relevant functional properties or whether the record specifies a commercial grade. Compare that description with the specification and any additional functionality-related tests.
- Compatibility: look for the relationship between the active substance and excipients, relevant excipient interactions, and the proposed container system. A list of individually acceptable materials does not explain their compatibility as a combination.
- Product performance: connect the test evidence to the intended dosage form and quality attributes. Where a preservative is used, distinguish measuring its chemical content from demonstrating antimicrobial effectiveness.
- Development continuity: identify which formulation and batch generated a cited result. FDA’s formulation-development discussion distinguishes relevant clinical, primary stability and proposed commercial formulations and calls for explanations of their differences.
- Evidence location: separate composition, development rationale, excipient controls and stability evidence. They answer different questions even when they concern the same ingredient.
The eCTD Module 3 quality structure provides the wider organisation for these records. EMA’s excipient guideline locates composition in 3.2.P.1, development in 3.2.P.2 and excipient controls in 3.2.P.4; product stability belongs in 3.2.P.8. This separation helps a reader identify what a document actually demonstrates before treating it as evidence for another purpose.
For example, a specification can establish the properties controlled for an incoming material. The development rationale addresses why that material and grade were chosen for the formulation. The product’s stability record addresses how the resulting formulation performs over storage. Reading those records together supports a more complete assessment than relying on one document to answer all three questions.
Common misunderstandings
Inactive does not mean functionless
FDA’s active/inactive distinction is based on the ingredient’s intended role. It does not mean excipients have no effect on the product’s properties. EMA describes stabilisers, emulsifiers, solubilisers and other functional components, while Q8(R2) asks for an explanation of their effects on stability, bioavailability or manufacture. Their contribution needs to be understood in the formulation where they are used.
An ingredient database is not a finished formulation
FDA’s Inactive Ingredient Database contains information about ingredients in approved final dosage forms, organised by ingredient, administration route and dosage form. FDA describes previous use as potentially relevant to later development in a similar context. A database entry is therefore evidence of a particular use context; it does not supply a transferable product recipe or establish the suitability of every new combination.
A material specification does not answer every performance question
EMA explicitly allows additional tests and acceptance criteria where functionality-related characteristics require them. Compliance with a material monograph and performance in the intended product answer different questions. The product-specific explanation connects the material’s controlled properties with its documented function, rather than assuming that the material name alone supplies that connection.
Preservative content and preservative effectiveness are distinct
Q8(R2) distinguishes chemical testing for preservative content from demonstrating antimicrobial effectiveness during development. EMA also addresses preservative levels during stability testing and effectiveness under simulated use for relevant multidose, non-solid products. A result showing that a preservative is present does not replace the separate evidence that the preservation system performs as intended.
Sources
- NIH Clinicalinfo: Formulation, checked 2026-11-17.
- FDA: Q8(R2) Pharmaceutical Development, particularly parent sections 2.1–2.6 and annex sections 2.1–2.2, checked 2026-11-17.
- FDA: Inactive Ingredients in Approved Drug Products Search: Frequently Asked Questions, checked 2026-11-17.
- EMA: Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product, Revision 2, checked 2026-11-17.
Data: Drug formulation evidence: FDA and EMA crosswalk
Original comparison of formulation evidence discussed in FDA Q8(R2) and the EMA excipient dossier guideline. Cells identify complementary development and documentation topics, with section references. This is a reading aid, not a universal testing specification.
| Evidence area | FDA Q8(R2) discussion | EMA excipient guideline discussion |
|---|---|---|
| Component role | Parent 2.1.2: relate excipient choice, concentration and relevant characteristics to its function. | 4.1: list excipient name, quantity, function and reference standard. |
| Material grade and properties | Parent 2.1.2: discuss characteristics influencing performance or manufacturability. | 4.1–4.2: identify commercial grade when needed to describe functional properties and explain its choice. |
| Compatibility | Parent 2.1.1–2.1.2: evaluate drug substance–excipient compatibility and relevant excipient interactions. | 4.2: establish compatibility with active substances and, where relevant, other excipients. |
| Function-related controls | Parent 2.1.2: demonstrate intended excipient functionality throughout product shelf life. | 4.3–4.4: additional functionality-related tests may be necessary, including relevant viscosity, emulsification or dispersion properties. |
| Novel excipient support | Parent 2.1.2: cross-reference supporting excipient safety information where appropriate in 3.2.P.4.6. | 4.6: provide manufacture, characterisation and controls with cross-references to supporting safety data. |
| Antimicrobial preservation | Parent 2.5: distinguish routine chemical content testing from effectiveness demonstrated during development. | 4.8: monitor preservative levels during stability; establish simulated in-use effectiveness for relevant multidose non-solid products. |
Sources
- FDA: Q8(R2) Pharmaceutical Development (accessed 2026-11-17)
- EMA: Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product, Revision 2 (accessed 2026-11-17)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







